 My name is Claire Siwa Prisha. I am a Welcome International Intermediate Fellow based at the Mahedan Offered Tropical Research Unit in Bangkok, Thailand. I lead a team to investigate the genetics basis of a bacterial infection called myeloidosis. So my research has been collecting and profiling the genetics of the bacteria that cause myeloidosis, the bacteria that can be collected from patients and from mental exposures as well as the genetics of the patients themselves. So we're creating the database to try to investigate the genetics factors in both the host and the bacteria that influence the disease acquisitions as well as the disease outcome. So one of the research highlights from our recently collected data sets is being that we could identify the bacterial genes or alleles that are more prevalent in disease-causing isolates compared to environmental isolates. And one of the top hits are genes that the bacteria use as the needles to puncture and get into the host cells. And coincidentally, this gene, SCP-1, has been ready-picked as a vaccine candidate. So these examples highlight how genetic studies can support the vaccines decide and the vaccines community seems to be quite pleased with the result. So the big questions in the field right now is how we can speed up the disease diagnosis. Currently, the gold standard to diagnose myeloidosis is the culture-confirmed approach. And this typically takes three to four days for the culture-confirmed result to arrive. However, within that waiting window, about 20% of patients died before the noted have got myeloidosis. And for the patients who know they've got myeloidosis, another 20% died within a month after admission. So there's a call for a demand to develop a rapid diagnostic test. So we team up with the local researchers to develop the cryptocast-based diagnostic. And this is based on the detections of nucleic acids of the bacteria. And using the genetics data that we've been collecting, we can identify the conserved regions as a target in the bacteria that are unique to the species that call myeloidosis, but cannot be identified in all the species as well as the human host. And our Crippus assays reduce the diagnostic time from three to four days to less than three hours. And currently, it has higher sensitivities of any rapid test of up to 93% as compared to 66% of the culture approached. And we hope that it can be a game changer. We strongly believe that with rapid diagnostic, we can identify patients faster. We can treat them with correct antibiotics faster. And we hope that that will help save more life from myeloidosis. I think a direct impact to save life worth a lot of funding. But the other message I would like to deliver is that any technologies developed in resource limited setting has its own advantages. It's not easy to develop something in resource constrained setting. But when we operate in this area that force creativity, and we have to decide our equipment to be very light, I strongly believe that any assays that are up and running in such setting can be operated in anywhere in this world. And that's why we think it's worth funding. I think we are very fortunate to be able to work in our current setting, even though it's resource limited. But we connect to patients. We learn how they suffer from myeloidosis. We learn the impact the disease had on their life. And we receive so many blessings from patients and relatives for the success of our research. And hopefully that's helped improve the life.